Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.
Altered myocardial energy metabolism has been linked to worsening of RV function in pulmonary arterial hypertension (PAH). The aim of this study was to evaluate RV glucose and fatty acid metabolism in vivo in a rat model of PAH using positron emission tomography (PET) and investigate the effects of Macitentan on RV substrate utilization.



PAH was induced in male Sprague-Dawley rats by a single subcutaneous injection of Sugen 5416 (20 mg/kg) followed by 3 weeks of hypoxia (10% oxygen). At week 5 post-injection, the PAH rats were randomized to Macitentan (30 mg/kg daily) treatment or no treatment. Substrate utilization was serially assessed 5 and 8 weeks post-injection with 2-[18F]fluoro-2-deoxyglucose (FDG) and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA) PET for glucose and fatty acid metabolism respectively and correlated with in vivo functional measurements.



PAH induction resulted in a 2.5-fold increase in RV FDG uptake (standardized uptake value (SUV) of normal control: 1.6 ± 0.4, week 5: 4.1 ± 1.9, week 8: 4.0 ± 1.6, P < 0.05 for all groups vs. control). RV FTHA showed twofold increased uptake at week 5 (SUV control: 1.50 ± 0.39, week 5: 3.06 ± 1.10, P = 0.03). Macitentan significantly decreased RV FDG uptake at 8 weeks (SUV: 2.5 ± 0.9, P = 0.04), associated with improved RV ejection fraction and reduced RV systolic pressure, while FTHA uptake was maintained.



PAH is associated with metabolic changes in the RV, characterized by a marked increase in FDG and FTHA uptake. Macitentan treatment reduced PAH severity and was associated with a decrease in RV FDG uptake and improved RV function.
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Katarzyna
K
Drozd
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Ali
A
Ahmadi
Ottawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada.
Yupu
Y
Deng
Ottawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada.
Baohua
B
Jiang
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Julia
J
Petryk
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Stephanie
S
Thorn
Ottawa Hospital Research Institute, 1053 Carling Ave, Ottawa, ON, Canada.
Duncan
D
Stewart
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada.
Rob
R
Beanlands
Department of Cardiac Imaging, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Robert A
RA
deKemp
Department of Radiology, Radio-Oncology and Nuclear Medicine, University of Montreal, Montreal, QC, Canada.|University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada.
Jean N
JN
DaSilva
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada. lmielniczuk@ottawaheart.ca.
Lisa M
LM
Mielniczuk
D000818:Animals; D004195:Disease Models, Animal; D065128:Endothelin Receptor Antagonists / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism*; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology; D000860:Hypoxia; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology*; D016278:Ventricular Function, Right / Q000187:drug effects*
D065128:Endothelin Receptor Antagonists; D005227:Fatty Acids; D011743:Pyrimidines; D013449:Sulfonamides; D005947:Glucose; C533860:macitentan
Fatty acid imaging; PET; fluorodeoxyglucose (FDG); heart failure; metabolism; microPET imaging
J Mol Med (Berl). 2013 Mar;91(3):333-46
23247844
Int J Cardiol. 2014 Dec 15;177(2):423-8
25305681
Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2304-9
16100246
Eur J Nucl Med Mol Imaging. 2002 Dec;29(12 ):1617-22
12458396
Eur Heart J Cardiovasc Imaging. 2016 Dec;17 (12 ):1424-1431
26060207
J Vasc Res. 2012;49(1):33-42
21985792
N Engl J Med. 2007 Mar 15;356(11):1140-51
17360992
Ann N Y Acad Sci. 2015 Nov;1358:68-81
26291180
Pulm Circ. 2013 Jan;3(1):144-52
23662191
Cardiovasc Res. 2012 Apr 1;94(1):77-86
22258630
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33
24355638
FASEB J. 2001 Feb;15(2):427-38
11156958
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):18-23
23406664
Circulation. 2010 Jun 22;121(24):2661-71
20529999
J Am Coll Cardiol. 1995 Dec;26(7):1581-5
7594089
J Cardiovasc Pharmacol. 2014 Nov;64(5):473-80
25084082
J Mol Med (Berl). 2010 Jan;88(1):47-60
19949938
Am J Physiol Lung Cell Mol Physiol. 2015 Sep 1;309(5):L435-40
26115672
J Am Coll Cardiol. 2009 Jun 30;54(1):1-15
19555834
Am J Physiol Lung Cell Mol Physiol. 2015 Mar 15;308(6):L523-38
25539851
Circulation. 1989 Nov;80(5):1198-206
2805258
Am J Respir Crit Care Med. 2012 Mar 15;185(6):670-9
22246173
Circulation. 2001 Jun 19;103(24):2961-6
11413087
J Mol Med (Berl). 2012 Jan;90(1):31-43
21874543
Pulm Circ. 2012 Oct;2(4):434-42
23372927
Circulation. 1997 Jan 21;95(2):313-5
9008441
N Engl J Med. 2013 Aug 29;369(9):809-18
23984728
Int J Cardiovasc Imaging. 2010 Jun;26(5):509-18
20140524
Circulation. 2006 Jun 6;113(22):2630-41
16735674
J Nucl Med. 2005 Jan;46(1):25-31
15632029
Circulation. 2010 Jun 29;121(25):2747-54
20547927